Protagonist Therapeutics (NASDAQ:PTGX) is set to announce its Q4 2025 earnings before the market opens on Friday, February 20th, with analysts anticipating a loss of ($0.53) per share. Recent insider selling includes CFO Asif Ali and Director William D. Waddill, with insiders having sold approximately $15.4 million worth of shares in the past 90 days. Despite the insider sales, the company holds a “Moderate Buy” consensus rating from analysts, with an average price target of $91.64.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Protagonist Therapeutics (PTGX) to Release Earnings on Friday
Protagonist Therapeutics (NASDAQ:PTGX) is set to announce its Q4 2025 earnings before the market opens on Friday, February 20th, with analysts anticipating a loss of ($0.53) per share. Recent insider selling includes CFO Asif Ali and Director William D. Waddill, with insiders having sold approximately $15.4 million worth of shares in the past 90 days. Despite the insider sales, the company holds a “Moderate Buy” consensus rating from analysts, with an average price target of $91.64.